157 results
8-K
EX-99.1
BPTH
Bio-Path Holdings Inc
8 Jan 20
Bio-Path Holdings Provides Clinical Update and 2020 Business Outlook
4:30pm
expects that plans for a pivotal trial would be discussed with the FDA.
Phase 2a Study of Prexigebersen to treat Chronic Myeloid Leukemia (CML) in Tyrosine … for accelerated and blast phase CML patients and will expand to other sites if feasible. Recent advances in the treatment of chronic phase CML patients
8-K
EX-99.1
BPTH
Bio-Path Holdings Inc
21 Nov 19
Bio-path Holdings Announces Clearance of Investigational New Drug Application for BP1002
8:20am
of BP1002, Targeting Bcl-2 Protein, to Treat Refractory/Relapsed Lymphoma and Chronic Lymphocytic Leukemia Patients
HOUSTON – November 21, 2019 – Bio … the ability of BP1002 to treat refractory/relapsed lymphoma and chronic lymphocytic leukemia patients.
BP1002 targets the protein Bcl-2, which
8-K
EX-99.1
BPTH
Bio-Path Holdings Inc
27 Dec 18
Bio-Path Holdings Provides Clinical Update and 2019 Business Outlook
4:31pm
, dasatinib, for the treatment of chronic myeloid leukemia (CML) in accelerated and blast phase patients. For 2019, additional sites are planned to be added … and enrollment planned to be opened across both phases of the disease, including imatinib-resistant chronic phase patients. The trial is currently being
8-K
EX-99.1
BPTH
Bio-Path Holdings Inc
6 Mar 20
Bio-path Holdings Reports Full Year 2019 Financial Results
7:10am
/relapsed lymphoma and chronic lymphocytic leukemia patients. Finally, we are nearing completion of IND-enabling studies of BP1003, our novel liposome … clinical trial will evaluate the ability of BP1002 to treat refractory/relapsed lymphoma and chronic lymphocytic leukemia patients.
Successfully Completed
8-K
EX-99.1
BPTH
Bio-Path Holdings Inc
14 Apr 20
Bio-Path Holdings to Present at the 2020 American Association for Cancer Research Annual Meeting
12:00am
, for the treatment of lymphomas and chronic lymphocytic leukemia.
Details for the virtual poster presentation are as follows:
Date: Monday, April 27, 2020 … candidate is BP1002, which targets the Bcl-2 protein and is planned to be evaluated for the treatment of lymphoma and chronic lymphocytic leukemia
8-K
EX-99.1
uyq5p n51gw
19 Nov 20
Bio-Path Holdings Announces First Patient Dosed in Phase 1 Clinical Trial of BP1002
4:30pm
8-K
EX-99.1
gm7t46hi
15 Nov 11
Bio-Path Holdings Reports Third Quarter 2011 Financial Results
12:00am
8-K
EX-99.1
39ykkh
10 Jan 24
Targeting Bcl-2 Protein Offers Potential Treatment for Patients Who Have Failed or Relapsed from Venetoclax-Based Frontline Therapy
4:10pm
8-K
EX-99.1
x5bnufxgc1vgw4gn
20 Mar 19
Bio-path Holdings Reports Full Year 2018 Financial Results
7:00am
8-K
EX-99.1
1npw3dvu
8 Mar 24
Bio-path Holdings Reports Full Year 2023 Financial Results
7:10am
8-K
EX-99.1
9cxb7vx23i uzbtmrm
13 Dec 11
Other Events
12:00am
8-K
EX-99.1
ui9lf2hl iqfg3pvsw8x
15 Aug 18
Bio-path Holdings Reports Second Quarter 2018 Financial Results
7:00am
8-K
EX-99.1
726n5rx1
15 May 24
Bio-Path Holdings Reports First Quarter 2024 Financial Results
7:10am
8-K
EX-99.1
71cdrkweetqv
15 Aug 13
Bio-Path Holdings Reports Second Quarter 2013
12:00am
8-K
EX-99.1
4y0 fpyw5
2 Apr 24
Bio-Path Holdings Provides 2024 Clinical and Operational Update
4:10pm